05:40 AM EST, 11/06/2026 (MT Newswires) -- Saniona (SANION.ST) intends to file its clinical trial application for SAN2668, its investigational drug for severe pediatric epilepsies, by the end of December. The company will submit the application through the EU Clinical Trials Information System, according to a Friday release. The application follows preclinical and chemistry, manufacturing and controls required to support a phase 1 clinical study for the drug.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.